Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why CytRx Corporation Shares Jumped

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of CytRx (NASDAQ: CYTR  ) , a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer, jumped as much as 14% after the Food and Drug Administration granted the company approval to extend the dosing of aldoxorubicin until disease progression in an upcoming phase 3 trial for soft-tissue sarcomas.

So what: The FDA's ruling is important because its previously outlined phase 3 design under its Special Protocol Assessment had called for treatment, and the study, to be stopped after six cycles. But following CytRx's phase 2b clinical results that utilized a 1,560 mg/m2 dose of doxorubicin, which would have been expected, on paper, to potentially cause cardiac toxicity, no such cardiotoxicities were noted. In other words, with CytRx now being able to dose until disease progression there could be an even greater progression-free survival and median overall survival benefit.

Now what: Everything is in the details, and the FDA's thumbs up to CytRx clearly shows that it likes what it's seen so far in terms of cardiovascular safety from aldoxorubicin. Obviously, there aren't many second-line-treatment options available for soft-tissue sarcomas, so this could be construed as mildly positive news for CytRx. I wouldn't, however, get too excited until I see its pivotal late-stage results, which are targeting a statistically significant improvement in progression-free survival as its primary endpoint.

CytRx is having a great day, but it may struggle to keep up with this top stock in 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special 
free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 27, 2014, at 2:11 PM, elalpha533 wrote:

    I think this one could be a BIG winner. I am buying the dips and adding to my position. The science behind aldoxorubicin seems solid and the result so far seem to back that up. Not to mention that it is only an improvement on a drug already in use.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2802969, ~/Articles/ArticleHandler.aspx, 9/1/2015 2:18:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 5 hours ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 3:59 PM
CYTR $2.46 Up +0.07 +2.93%
CytRx Corp CAPS Rating: **